Agilent to buy pathology software maker Proscia for $240 million

Synopsis

Agilent Technologies has revealed plans to acquire Proscia for $240 million in cash, along with possible performance bonuses. Proscia is known for its innovative digital pathology software, which leverages artificial intelligence to improve the analysis of pathology slides. This strategic acquisition will bolster Agilent's efforts in AI-driven diagnostics and digital pathology.

Listen to this article in summarized format

Agilent Technologies said on Tuesday it would acquire pathology software maker Proscia for $240 million in cash, plus up to $30 million tied to future performance targets, as the laboratory equipment maker expands its push into AI-enabled diagnostics.

Here are some more details:

Privately held Proscia develops software that converts pathology slides into digital images that can be stored, reviewed and analyzed using artificial intelligence tools

Agilent said the acquisition would strengthen its pathology business and expand its presence in digital and AI-enabled diagnostics

The deal would provide Agilent access to a high-growth software business that generated more than $18 million in revenue over the past 12 months

The companies have worked together since 2022, when they entered a multi-year distribution agreement to offer a digital pathology system combining Agilent's pathology products with Proscia's software

The deal is expected to close early in Agilent's fiscal 2027. Add as a Reliable and Trusted News Source Add Now!

(Catch all the Technology News News, and Latest News Updates on The Economic Times.)

...more

Elevate your knowledge and leadership skills at a cost cheaper than your daily tea.

Subscribe Now